Skip to main content
Top
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Research

Employment of digital gene expression profiling to identify potential pathogenic and therapeutic targets of fulminant hepatic failure

Authors: En-Qiang Chen, Lang Bai, Dao-Yin Gong, Hong Tang

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

Background

The dysregulated cytokine metabolism and activity are crucial to the development of fulminant hepatic failure (FHF), and many different cytokines have been identified. However, the precise gene expression profile and their interactions association with FHF are yet to be further elucidated.

Methods

In this study, we detected the digital gene expression profile (DGEP) by high-throughput sequencing in normal and FHF mouse liver, and the candidate genes and potential targets for FHF therapy were verified. And the FHF mouse model was induced by D-Galactosamine (GalN)/lipopolysaccharide (LPS).

Results

Totally 12727 genes were detected, and 3551 differentially expressed genes (DEGs) were obtained from RNA-seq data in FHF mouse liver. In FHF mouse liver, many of those DEGs were identified as differentially expressed in metabolic process, biosynthetic process, response to stimulus and response to stress, etc. Similarly, pathway enrichment analysis in FHF mouse liver showed that many significantly DEGs were also enriched in metabolic pathways, apoptosis, chemokine signaling pathways, etc. Considering the important role of nuclear factor-kappa B (NF-κB) in metabolic regulation and delicate balance between cell survival and death, several DEGs involved in NF-κB pathway were selected for experimental validation. As compared to normal control, NF-κBp65 and its inhibitory protein IκBα were both significantly increased, and NF-κB targeted genes including tumor necrosis factor α(TNFα), inducible nitric oxide synthase (iNOS), interleukin-1β, chemokines CCL3 and CCL4 were also increased in hepatic tissues of FHF. In addition, after NF-κB was successfully pre-blocked, there were significant alteration of hepatic pathological damage and mortality of FHF mouse model.

Conclusions

This study provides the globe gene expression profile of FHF mouse liver, and demonstrates the possibility of NF-κB gene as a potential therapeutic target for FHF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008;14 Suppl 2:S67–79.PubMedCrossRef Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008;14 Suppl 2:S67–79.PubMedCrossRef
2.
go back to reference Graziadei IW. The clinical challenges of acute on chronic liver failure. Liver Int. 2011;31 Suppl 3:24–6.PubMedCrossRef Graziadei IW. The clinical challenges of acute on chronic liver failure. Liver Int. 2011;31 Suppl 3:24–6.PubMedCrossRef
3.
go back to reference Liu Q. Role of cytokines in the pathophysiology of acute-on-chronic liver failure. Blood Purif. 2009;28:331–41.PubMedCrossRef Liu Q. Role of cytokines in the pathophysiology of acute-on-chronic liver failure. Blood Purif. 2009;28:331–41.PubMedCrossRef
4.
go back to reference Rutherford A, Chung RT. Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin Liver Dis. 2008;28:167–74.PubMedCrossRef Rutherford A, Chung RT. Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin Liver Dis. 2008;28:167–74.PubMedCrossRef
5.
go back to reference Dominik A, Stange J, Pfensig C, Borufka L, Weiss-Reining H, Eggert M. Reduction of elevated cytokine levels in acute/acute-on-chronic liver failure using super-large pore albumin dialysis treatment: an In vitro study. Ther Apher Dial. 2014;18:347–52.PubMedCrossRef Dominik A, Stange J, Pfensig C, Borufka L, Weiss-Reining H, Eggert M. Reduction of elevated cytokine levels in acute/acute-on-chronic liver failure using super-large pore albumin dialysis treatment: an In vitro study. Ther Apher Dial. 2014;18:347–52.PubMedCrossRef
6.
go back to reference Cobb JP, Laramie JM, Stormo GD, Morrissey JJ, Shannon WD, Qiu Y, et al. Sepsis gene expression profiling: murine splenic compared with hepatic responses determined by using complementary DNA microarrays. Crit Care Med. 2002;30:2711–21.PubMedCrossRef Cobb JP, Laramie JM, Stormo GD, Morrissey JJ, Shannon WD, Qiu Y, et al. Sepsis gene expression profiling: murine splenic compared with hepatic responses determined by using complementary DNA microarrays. Crit Care Med. 2002;30:2711–21.PubMedCrossRef
7.
go back to reference El-Metwally S, Hamza T, Zakaria M, Helmy M. Next-generation sequence assembly: four stages of data processing and computational challenges. PLoS Comput Biol. 2013;9:e1003345.PubMedCentralPubMedCrossRef El-Metwally S, Hamza T, Zakaria M, Helmy M. Next-generation sequence assembly: four stages of data processing and computational challenges. PLoS Comput Biol. 2013;9:e1003345.PubMedCentralPubMedCrossRef
9.
go back to reference Wang W, Qin Z, Feng Z, Wang X, Zhang X. Identifying differentially spliced genes from two groups of RNA-seq samples. Gene. 2013;518:164–70.PubMedCrossRef Wang W, Qin Z, Feng Z, Wang X, Zhang X. Identifying differentially spliced genes from two groups of RNA-seq samples. Gene. 2013;518:164–70.PubMedCrossRef
10.
go back to reference Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, et al. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One. 2011;6:e26168.PubMedCentralPubMedCrossRef Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W, et al. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. PLoS One. 2011;6:e26168.PubMedCentralPubMedCrossRef
11.
go back to reference Chen EQ, Gong DY, Leng XH, Bai L, Liu C, Wang LC, et al. Inhibiting the expression of hepatocyte nuclear factor 4 alpha attenuates lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. Hepatobiliary Pancreat Dis Int. 2012;11:624–9.PubMedCrossRef Chen EQ, Gong DY, Leng XH, Bai L, Liu C, Wang LC, et al. Inhibiting the expression of hepatocyte nuclear factor 4 alpha attenuates lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. Hepatobiliary Pancreat Dis Int. 2012;11:624–9.PubMedCrossRef
12.
go back to reference Axiotis CA, Monteagudo C, Merino MJ, LaPorte N, Neumann RD. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol. 1991;138:799–806.PubMedCentralPubMed Axiotis CA, Monteagudo C, Merino MJ, LaPorte N, Neumann RD. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol. 1991;138:799–806.PubMedCentralPubMed
13.
14.
go back to reference Sun S, Guo Y, Zhao G, Zhou X, Li J, Hu J, et al. Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS One. 2011;6:e26838.PubMedCentralPubMedCrossRef Sun S, Guo Y, Zhao G, Zhou X, Li J, Hu J, et al. Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS One. 2011;6:e26838.PubMedCentralPubMedCrossRef
15.
go back to reference Duan ZP, Chin Y. Prospect of severe hepatitis and liver failure. Zhonghua Gan Zang Bing Za Zhi. 2009;17:10–1.PubMed Duan ZP, Chin Y. Prospect of severe hepatitis and liver failure. Zhonghua Gan Zang Bing Za Zhi. 2009;17:10–1.PubMed
16.
go back to reference Su Z, Ning B, Fang H, Hong H, Perkins R, Tong W, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn. 2011;11:333–43.PubMed Su Z, Ning B, Fang H, Hong H, Perkins R, Tong W, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn. 2011;11:333–43.PubMed
17.
go back to reference Yang Q, Shi Y, He J, Chen Z. The evolving story of macrophages in acute liver failure. Immunol Lett. 2012;147:1–9.PubMedCrossRef Yang Q, Shi Y, He J, Chen Z. The evolving story of macrophages in acute liver failure. Immunol Lett. 2012;147:1–9.PubMedCrossRef
18.
go back to reference McGill MR, Jaeschke H. Apoptosis or necrosis in acetaminophen-induced acute liver failure? New insights from mechanistic biomarkers*. Crit Care Med. 2013;41:2653–4.PubMedCrossRef McGill MR, Jaeschke H. Apoptosis or necrosis in acetaminophen-induced acute liver failure? New insights from mechanistic biomarkers*. Crit Care Med. 2013;41:2653–4.PubMedCrossRef
19.
go back to reference Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol Chem. 2009;390:965–76.PubMedCentralPubMedCrossRef Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol Chem. 2009;390:965–76.PubMedCentralPubMedCrossRef
20.
go back to reference Robinson SM, Mann DA. Role of nuclear factor kappaB in liver health and disease. Clin Sci (Lond). 2010;118:691–705.CrossRef Robinson SM, Mann DA. Role of nuclear factor kappaB in liver health and disease. Clin Sci (Lond). 2010;118:691–705.CrossRef
21.
go back to reference Wu YL, Lian LH, Wan Y, Nan JX. Baicalein inhibits nuclear factor-kappaB and apoptosis via c-FLIP and MAPK in D-GalN/LPS induced acute liver failure in murine models. Chem Biol Interact. 2010;188:526–34.PubMedCrossRef Wu YL, Lian LH, Wan Y, Nan JX. Baicalein inhibits nuclear factor-kappaB and apoptosis via c-FLIP and MAPK in D-GalN/LPS induced acute liver failure in murine models. Chem Biol Interact. 2010;188:526–34.PubMedCrossRef
22.
go back to reference Campbell KJ, Perkins ND. Regulation of NF-kappaB function. Biochem Soc Symp. 2006;73:165–80.PubMed Campbell KJ, Perkins ND. Regulation of NF-kappaB function. Biochem Soc Symp. 2006;73:165–80.PubMed
23.
go back to reference Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002;64:883–8.PubMedCrossRef Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002;64:883–8.PubMedCrossRef
24.
go back to reference Jayakumar AR, Bethea JR, Tong XY, Gomez J, Norenberg MD. NF-kappaB in the mechanism of brain edema in acute liver failure: studies in transgenic mice. Neurobiol Dis. 2011;41:498–507.PubMedCentralPubMedCrossRef Jayakumar AR, Bethea JR, Tong XY, Gomez J, Norenberg MD. NF-kappaB in the mechanism of brain edema in acute liver failure: studies in transgenic mice. Neurobiol Dis. 2011;41:498–507.PubMedCentralPubMedCrossRef
25.
go back to reference Erener S, Petrilli V, Kassner I, Minotti R, Castillo R, Santoro R, et al. Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-kappaB target genes. Mol Cell. 2014;46:200–11.CrossRef Erener S, Petrilli V, Kassner I, Minotti R, Castillo R, Santoro R, et al. Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-kappaB target genes. Mol Cell. 2014;46:200–11.CrossRef
27.
go back to reference Baltathakis I, Alcantara O, Boldt DH. Expression of different NF-kappaB pathway genes in dendritic cells (DCs) or macrophages assessed by gene expression profiling. J Cell Biochem. 2001;83:281–90.PubMedCrossRef Baltathakis I, Alcantara O, Boldt DH. Expression of different NF-kappaB pathway genes in dendritic cells (DCs) or macrophages assessed by gene expression profiling. J Cell Biochem. 2001;83:281–90.PubMedCrossRef
Metadata
Title
Employment of digital gene expression profiling to identify potential pathogenic and therapeutic targets of fulminant hepatic failure
Authors
En-Qiang Chen
Lang Bai
Dao-Yin Gong
Hong Tang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-015-0380-9

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.